Yüklüyor......

CTNI-15. CLINICAL EFFICACY OF ONC201 IN NEWLY DIAGNOSED DIPG AND IN PREVIOUSLY IRRADIATED PEDIATRIC H3 K27M-MUTANT GLIOMAS

ONC201, an anti-cancer DRD2 antagonist and ClpP agonist, is in Phase II trials for adult H3 K27M-mutant diffuse midline gliomas. In adults, the recommended phase 2 dose (RP2D) of 625mg ONC201 once a week has been established as a biologically active dose that is well tolerated. Radiographic regressi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Gardner, Sharon, Koschmann, Carl, Tarapore, Rohinton S, Allen, Jeffrey, Zaky, Wafik, Odia, Yazmin, Hall, Matthew, Daghistani, Doured, Khatib, Ziad, Aguilera, Dolly, MacDonald, Tobey, Fouladi, Maryam, McGovern, Susan, Mueller, Sabine, Kline, Cassie, Vitanza, Nicholas, Lu, Guangrong, Allen, Joshua, Khatua, Soumen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650473/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.182
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!